Sotera Health’s first quarter saw year-on-year revenue growth driven by strong performance in Sterigenics and Nordion, with the latter benefiting from favorable Cobalt-60 harvest timing. Despite beating Wall Street’s revenue expectations, the market reacted negatively to the results. Management attributed growth to improved pricing, resilient customer demand, and effective operational execution, while also noting lingering headwinds such as weather-related disruptions and volume softness at Nelson Labs. CEO Michael Petras acknowledged, “March was the best month on volume we have had in the last three or four years,” highlighting a positive shift late in the quarter.
Is now the time to buy SHC? Find out in our full research report (it’s free for active Edge members).
Sotera Health Company (SHC) Q1 CY2026 Highlights:
- Revenue: $280 million vs analyst estimates of $270.4 million (10% year-on-year growth, 3.6% beat)
- Adjusted EPS: $0.18 vs analyst estimates of $0.17 (in line)
- Adjusted EBITDA: $134.7 million vs analyst estimates of $131.4 million (48.1% margin, 2.5% beat)
- The company reconfirmed its revenue guidance for the full year of $1.24 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $0.97 at the midpoint
- Operating Margin: 27.1%, up from 22.4% in the same quarter last year
- Organic Revenue rose 6.5% year on year (beat)
- Market Capitalization: $4.4 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Sotera Health Company’s Q1 Earnings Call
- Thomas Keller (BMO Capital Markets) asked about Sterigenics’ strategy realignment and volume/mix benefit; CEO Michael Petras explained the business is focused on high-growth segments and saw a strong finish to the quarter, especially in March.
- Brett Fishbin (KeyBanc Capital Markets) questioned whether Q1 was the lightest quarter for Sterigenics and trends in med device and bioprocessing volumes; Petras confirmed Q2 should be similar in growth, with med device solid and bioprocessing up from a small base.
- Patrick Donnelly (Citi) asked about Sterigenics’ volume progression through the quarter and margin outlook; Petras highlighted weather impacts early in Q1 but record volume in March and April, while CFO Jonathan Lyons expects continued margin improvement.
- William Blair (Analyst) inquired about comp issues in Sterigenics’ Q2 guide and Nelson Labs’ segment margin outlook; Petras clarified Q2 faces a tough comparison and expects Nelson Labs margins to improve to low- to mid-30s by year-end.
- Sam (Barclays) asked about the impact of potential ethylene oxide rule changes and implications for capital expenditures; Petras said the team is executing upgrades regardless of regulatory uncertainty and feels well positioned for any outcome.
Catalysts in Upcoming Quarters
In future quarters, our analysts will be watching (1) execution on Sterigenics’ new capacity ramp and the onboarding of a significant customer, (2) regulatory clarity on ethylene oxide emissions and its impact on competitive positioning, and (3) sustained margin improvement in both Sterigenics and Nelson Labs. The pace of recovery in Nelson Labs’ testing volumes and further progress on board and management transitions will also be important to track.
Sotera Health Company currently trades at $15.26, in line with $15.39 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
